The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Updated results of a phase 2 study: Timdarpacept (IMM01) combined with azacitidine (AZA) as the first-line treatment in adults with chronic myelomonocytic leukemia (CMML).
 
Hongyan Tong
No Relationships to Disclose
 
Sujun Gao
No Relationships to Disclose
 
Wei Yang
No Relationships to Disclose
 
Junmin Li
No Relationships to Disclose
 
Qingsong Yin
No Relationships to Disclose
 
Xingli Zhao
No Relationships to Disclose
 
Xiaojing Yan
No Relationships to Disclose
 
Sanfang Tu
No Relationships to Disclose
 
Fei Li
No Relationships to Disclose
 
Haiping Yang
No Relationships to Disclose
 
Ronghua Hu
No Relationships to Disclose
 
Shaoyuan Wang
No Relationships to Disclose
 
Liya Ma
No Relationships to Disclose
 
Zheng Dong
Employment - ImmuneOnco Biopharmaceuticals
Honoraria - ImmuneOnco Biopharmaceuticals
 
Qiying Lu
Employment - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
Honoraria - ImmuneOnco Biopharmaceuticals
 
Wenzhi Tian
Employment - ImmuneOnco Biopharmaceuticals
Leadership - ImmuneOnco Biopharmaceuticals
Stock and Other Ownership Interests - ImmuneOnco Biopharmaceuticals
Honoraria - ImmuneOnco Biopharmaceuticals
 
Zhi-Jian Xiao
No Relationships to Disclose
 
Jianxiang Wang
Consulting or Advisory Role - Abbvie